IL258866A - Binding molecules that inhibit cancer growth - Google Patents

Binding molecules that inhibit cancer growth

Info

Publication number
IL258866A
IL258866A IL258866A IL25886618A IL258866A IL 258866 A IL258866 A IL 258866A IL 258866 A IL258866 A IL 258866A IL 25886618 A IL25886618 A IL 25886618A IL 258866 A IL258866 A IL 258866A
Authority
IL
Israel
Prior art keywords
binding molecules
cancer growth
inhibit cancer
inhibit
growth
Prior art date
Application number
IL258866A
Other languages
Hebrew (he)
Other versions
IL258866B1 (en
IL258866B2 (en
Inventor
Logtenberg Ton
Throsby Mark
Carolus Clevers Johannes
Gerhardus Jacob Vries Robert
Batlle Eduard
Herpers Bram
Original Assignee
Logtenberg Ton
Inst Catalana Recerca Estudis Avancats
Koninklijke Nederlandse Akademie Van Wetenschappen
Throsby Mark
Merus Nv
Ocello B V
Institute For Res In Biomedicine Irb Barcelona
Carolus Clevers Johannes
Gerhardus Jacob Vries Robert
Batlle Eduard
Herpers Bram
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Logtenberg Ton, Inst Catalana Recerca Estudis Avancats, Koninklijke Nederlandse Akademie Van Wetenschappen, Throsby Mark, Merus Nv, Ocello B V, Institute For Res In Biomedicine Irb Barcelona, Carolus Clevers Johannes, Gerhardus Jacob Vries Robert, Batlle Eduard, Herpers Bram filed Critical Logtenberg Ton
Priority claimed from PCT/NL2016/050726 external-priority patent/WO2017069628A2/en
Publication of IL258866A publication Critical patent/IL258866A/en
Publication of IL258866B1 publication Critical patent/IL258866B1/en
Publication of IL258866B2 publication Critical patent/IL258866B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
IL258866A 2015-10-23 2016-10-21 Binding molecules that inhibit cancer growth IL258866B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15191343 2015-10-23
PCT/NL2016/050726 WO2017069628A2 (en) 2015-10-23 2016-10-21 Binding molecules that inhibit cancer growth

Publications (3)

Publication Number Publication Date
IL258866A true IL258866A (en) 2018-06-28
IL258866B1 IL258866B1 (en) 2023-12-01
IL258866B2 IL258866B2 (en) 2024-04-01

Family

ID=54360198

Family Applications (1)

Application Number Title Priority Date Filing Date
IL258866A IL258866B2 (en) 2015-10-23 2016-10-21 Binding molecules that inhibit cancer growth

Country Status (1)

Country Link
IL (1) IL258866B2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968554A4 (en) * 2013-03-14 2016-10-26 Oncomed Pharm Inc Met-binding agents and uses thereof

Also Published As

Publication number Publication date
IL258866B1 (en) 2023-12-01
IL258866B2 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
HK1253914A1 (en) Binding molecules that inhibit cancer growth
HK1251407A1 (en) Methods for treating cancer
HK1252791A1 (en) Binding molecules with modified j-chain
LT3377516T (en) Composition for treating cancer
GB201612520D0 (en) Binding molecules
IL277261A (en) Small molecules against cancer
SG11201705583XA (en) Cxcr4 binding molecules
GB201702091D0 (en) Specific binding molecules
HK1250944A1 (en) Methods for treating cancer
HK1245120A1 (en) Novel therapies for cancer
DK3292140T3 (en) Immunterapeutikum mod cancer
HK1250942A1 (en) Methods for treating cancer
HK1250943A1 (en) Methods for treating cancer
ZA201707024B (en) Cancer treatment composition
GB201508480D0 (en) Cancer
IL258866A (en) Binding molecules that inhibit cancer growth
GB2546773B (en) Cancer
GB201522433D0 (en) Cancer treatment
PT3365373T (en) Binding molecules that inhibit cancer growth
GB201508729D0 (en) Binding molecules
GB201503668D0 (en) Liver cancer